18.93
3.81%
+0.695
MediWound Ltd stock is currently priced at $18.93, with a 24-hour trading volume of 40,741.
It has seen a +3.81% increased in the last 24 hours and a +32.88% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $18.13 pivot point. If it approaches the $18.98 resistance level, significant changes may occur.
Previous Close:
$18.24
Open:
$18.2
24h Volume:
40,741
Market Cap:
$173.13M
Revenue:
$18.69M
Net Income/Loss:
$-6.72M
P/E Ratio:
-7.7922
EPS:
-2.43
Net Cash Flow:
$-16.93M
1W Performance:
+20.15%
1M Performance:
+32.88%
6M Performance:
+143.69%
1Y Performance:
+64.51%
MediWound Ltd Stock (MDWD) Company Profile
Name
MediWound Ltd
Sector
Industry
Phone
972 7 797 14100
Address
42 Hayarkon Street, Yavne
MediWound Ltd Stock (MDWD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-22-22 | Initiated | Maxim Group | Buy |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Sep-23-20 | Initiated | BTIG Research | Buy |
Nov-28-16 | Initiated | Aegis Capital | Buy |
Aug-17-16 | Initiated | Wells Fargo | Outperform |
Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
MediWound Ltd Stock (MDWD) Latest News
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
Zacks Investment Research
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
Zacks Investment Research
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
Zacks Investment Research
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
MediWound Ltd Stock (MDWD) Financials Data
MediWound Ltd (MDWD) Revenue 2024
MDWD reported a revenue (TTM) of $18.69 million for the quarter ending December 31, 2023, a -29.48% decline year-over-year.
MediWound Ltd (MDWD) Net Income 2024
MDWD net income (TTM) was -$6.72 million for the quarter ending December 31, 2023, a +65.73% increase year-over-year.
MediWound Ltd (MDWD) Cash Flow 2024
MDWD recorded a free cash flow (TTM) of -$16.93 million for the quarter ending December 31, 2023, a -36.09% decrease year-over-year.
MediWound Ltd (MDWD) Earnings per Share 2024
MDWD earnings per share (TTM) was -$0.77 for the quarter ending December 31, 2023, a +80.00% growth year-over-year.
About MediWound Ltd
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Cap:
|
Volume (24h):